Kathy O’Shaughnessy brings more than 18 years of experience in clinical and regulatory affairs in medical devices to RefleXion including significant experience guiding both 510(k) and PMA devices through the regulatory process in the US and globally.
O’Shaughnessy joined RefleXion in 2016 as vice president of regulatory and quality.
Prior to joining RefleXion, O’Shaughnessy was vice president of clinical, regulatory and quality for Miramar Labs, which was acquired by Sientra.
Her tenure also includes senior level executive positions in clinical and regulatory affairs at Allux Medical, Xoft, and R2 Technology (acquired by Hologic).
O’Shaughnessy received a Bachelor of Science in Physics and Math from the University of Victoria, Canada, a Master of Science in Physics and a Ph.D. in Physics, both from Stanford University.